33,284 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Purchased by Ontario Teachers Pension Plan Board

Ontario Teachers Pension Plan Board acquired a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) in the 4th quarter, Holdings Channel.com reports. The firm acquired 33,284 shares of the company’s stock, valued at approximately $394,000.

A number of other large investors also recently added to or reduced their stakes in the business. FMR LLC raised its stake in shares of Roivant Sciences by 0.3% during the fourth quarter. FMR LLC now owns 49,301,583 shares of the company’s stock worth $583,238,000 after buying an additional 156,527 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Roivant Sciences by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock valued at $521,553,000 after acquiring an additional 2,404,232 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Roivant Sciences by 49.7% in the 4th quarter. Invesco Ltd. now owns 9,515,058 shares of the company’s stock valued at $112,563,000 after purchasing an additional 3,159,603 shares during the period. Geode Capital Management LLC lifted its stake in shares of Roivant Sciences by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 7,771,831 shares of the company’s stock valued at $91,968,000 after purchasing an additional 26,727 shares during the period. Finally, Norges Bank bought a new position in shares of Roivant Sciences in the 4th quarter worth $52,443,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th.

Roivant Sciences Trading Up 1.3 %

NASDAQ:ROIV opened at $10.15 on Friday. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $13.06. The stock has a 50-day moving average price of $10.34 and a two-hundred day moving average price of $11.18. The stock has a market cap of $7.24 billion, a price-to-earnings ratio of -67.66 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Sell-side analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 218,041 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.42, for a total transaction of $2,271,987.22. Following the sale, the chief operating officer now directly owns 896,869 shares of the company’s stock, valued at approximately $9,345,374.98. This represents a 19.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the transaction, the chief accounting officer now owns 163,264 shares of the company’s stock, valued at $1,702,843.52. The trade was a 58.22 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,395,541 shares of company stock worth $15,028,538. Insiders own 7.90% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.